Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma

Ibrutinib, a bruton’s tyrosine kinase (BTK) inhibitor, provokes robust clinical responses in aggressive mantle cell lymphoma (MCL), yet many patients relapse with lethal Ibrutinib-resistant (IR) disease. Here, using genomic, chemical proteomic, and drug screen profiling, we report that enhancer remo...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cell Rep
Главные авторы: Zhao, Xiaohong, Wang, Michelle Y., Jiang, Huijuan, Lwin, Tint, Park, Paul M., Gao, Jing, Meads, Mark B., Ren, Yuan, Li, Tao, Sun, Jiao, Fahmi, Naima Ahmed, Singh, Satishkumar, Sehgal, Lalit, Wang, Xuefeng, Silva, Ariosto S., Sotomayor, Eduardo M., Shain, Kenneth H., Cleveland, John L., Wang, Michael, Zhang, Wei, Qi, Jun, Shah, Bijal D., Tao, Jianguo
Формат: Artigo
Язык:Inglês
Опубликовано: 2021
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8057695/
https://ncbi.nlm.nih.gov/pubmed/33730585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2021.108870
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы